News
CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and ...
Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback